Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thyroid and osteoporosis]

J Földes1, P Lakatos

  • 1Semmelweis Orvostudományi Egyetem, I. sz. Belklinika, Budapest.

Orvosi Hetilap
|June 23, 1996
PubMed
Summary
This summary is machine-generated.

Overt hyperthyroidism increases bone resorption and osteoporosis risk. Subclinical hyperthyroidism may affect postmenopausal women, necessitating careful levothyroxine dosing to avoid TSH suppression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milk-alkali syndrome due to regular consumption of thermal water.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Neural mechanisms of mismatch negativity dysfunction in schizophrenia.

Molecular psychiatry·2017
Same author

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.

Oral diseases·2017
Same author

Calcium regulation of HCN channels supports persistent activity in a multiscale model of neocortex.

Neuroscience·2016
Same author

Multi-Scale Entrainment of Coupled Neuronal Oscillations in Primary Auditory Cortex.

Frontiers in human neuroscience·2015
Same author

A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same journal

[The application of artificial intelligence in healthcare: benefits, challenges, and issues of responsibility].

Orvosi hetilap·2026
Same journal

[Long-COVID syndrome and lung-specific abnormalities following COVID-19].

Orvosi hetilap·2026
Same journal

[Validation of the Vaccination Attitudes Examination (VAX) scale in Hungary].

Orvosi hetilap·2026
Same journal

Orvosi hetilap·2026
Same journal

[The Hungarian short version and psychometric properties of the Activities-specific Balance Confidence Scale for assessing fall risk].

Orvosi hetilap·2026
Same journal

[Hungarian primary care: facts, problems and expectations].

Orvosi hetilap·2026
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Osteoporosis Research

Context:

  • Overt hyperthyroidism significantly alters bone metabolism, leading to increased bone turnover with a resorption predominance.
  • New sensitive markers accurately reflect these metabolic changes in hyperthyroid patients.
  • Overt hyperthyroidism is a confirmed risk factor for developing osteoporosis.

Purpose:

  • To investigate the impact of overt and subclinical hyperthyroidism on bone metabolism and osteoporosis risk.
  • To evaluate the effectiveness of hyperthyroid disease treatment on bone health.
  • To provide recommendations for levothyroxine replacement therapy in postmenopausal women.

Summary:

  • Hyperthyroidism causes increased bone resorption, elevating osteoporosis risk. While osteopenia improves with treatment, full recovery can take years.

Related Experiment Videos

  • Subclinical hyperthyroidism does not appear to cause osteoporosis in premenopausal women but may contribute to osteopenia in some postmenopausal women.
  • For postmenopausal women on levothyroxine, avoid TSH-suppressing doses; use the lowest effective dose if suppression is necessary.

    • Impact:

    • Highlights overt hyperthyroidism as a significant risk factor for osteoporosis.
    • Differentiates the bone health impact of subclinical hyperthyroidism in premenopausal versus postmenopausal women.
    • Offers crucial guidance on levothyroxine dosage to mitigate bone loss in postmenopausal women.